What is Akeso?
Akeso, Inc. operates at the intersection of advanced biotechnology and clinical application, distinguished by its proprietary ACE Platform. This end-to-end research and development engine integrates cutting-edge technologies, including Tetrabody and Dual-Shield ADCT, to streamline the discovery of next-generation antibody drugs. By focusing on high-burden diseases—specifically oncology, autoimmune, and metabolic conditions—Akeso has established a unique market position that balances scientific rigor with commercial scalability.
The company's operational strategy is defined by a commitment to global accessibility, aiming to democratize access to innovative treatments. Through a combination of internal R&D excellence and strategic licensing agreements, Akeso has successfully navigated the complexities of the biopharmaceutical sector, creating significant value for both its stakeholders and the global patient population. Its ability to maintain a competitive edge in a crowded therapeutic market is largely attributed to its focus on modular, high-efficiency drug development processes.
How much funding has Akeso raised?
Akeso has raised a total of $422.2M across 4 funding rounds:
Series A
$19.5M
Series B
$2.7M
Series D
$150M
Share Placement
$250M
Series A (2015): $19.5M with participation from Qianhai Xino, Shenzhen Capital Group, and CCB Capital
Series B (2017): $2.7M led by ShenZhen GTJA Investment Group
Series D (2019): $150M supported by Loyal Valley Capital, AIHC Capital, Sino Biopharmaceutical,, Lake Bleu Capital, and OrbiMed
Share Placement (2024): $250M, investors not publicly disclosed
Key Investors in Akeso
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with a deep expertise in life sciences innovation.
Loyal Valley Capital
A prominent investment firm that focuses on identifying and supporting high-growth companies within the Chinese market, particularly those demonstrating strong technological differentiation.
AIHC Capital
A strategic investment group dedicated to the healthcare and life sciences sectors, providing essential capital and operational guidance to companies developing innovative therapeutic solutions.
What's next for Akeso?
With the recent infusion of capital, Akeso is well-positioned to transition into its next phase of enterprise-level growth. The strategic focus will likely center on the acceleration of its late-stage clinical pipeline and the expansion of its international footprint. By deepening its collaborative efforts with global partners, the company aims to maximize the commercial potential of its ACE Platform while continuing to push the boundaries of antibody-based therapeutic innovation.
Looking ahead, the company is expected to prioritize the optimization of its manufacturing capabilities and the scaling of its commercial operations. As it navigates the evolving regulatory landscape, Akeso's ability to maintain its momentum will be critical in sustaining its leadership in the biopharmaceutical industry. The firm remains committed to its core objective of delivering transformative medical solutions, ensuring that its technological advancements translate into tangible clinical outcomes for patients worldwide.
